Trial Profile
An Open Label Trial to Assess the Safety and Efficacy of Burosumab (KRN23), an Investigational Antibody to FGF23, in a Single Pediatric Patient With Epidermal Nevus Syndrome(ENS) and Associated Hypophosphatemic Rickets
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Burosumab (Primary)
- Indications Nevus; X-linked dominant hypophosphataemic rickets
- Focus Therapeutic Use
- 14 Jan 2020 Status changed from active, no longer recruiting to completed.
- 01 Apr 2019 Planned End Date changed from 1 Jan 2019 to 30 Jun 2019.
- 01 Apr 2019 Planned primary completion date changed from 1 Jan 2019 to 30 Jun 2019.